【摘要】 目的 探討經(jīng)尿道等離子雙極電切術(shù)（PKRP）治療前列腺增生的安全性及臨床療效。 方法 2009年2-12月，采用PKRP治療前列腺增生患者76例，記錄手術(shù)時(shí)間、手術(shù)療效及術(shù)后并發(fā)癥。 結(jié)果 患者手術(shù)時(shí)間35～130 min，平均55 min。術(shù)中失血60～150 mL，均未輸血。手術(shù)切除前列腺質(zhì)量18～72 g。無(wú)直腸和膀胱穿孔，無(wú)電切綜合征（TURS）及閉孔神經(jīng)反射發(fā)生，無(wú)一例發(fā)生真性尿失禁，無(wú)死亡。術(shù)后隨訪2～6個(gè)月，IPSS評(píng)分平均為9分，最大尿流率平均為16.7 mL/s。 結(jié)論 PKRP是治療前列腺增生的理想方法之一。【Abstract】 Objective To evaluate the efficacy of transurethral plasmakinetic resection of the prostate (PKRP) on benign prostatic hyperplasia. Methods A total of 76 patients with benign prostatic hyperplasia from February to December 2009 were treated with PKRP. The operative duration, therapeutic effect and postoperative complications were observed and recorded. Results The operative duration ranged from 35 to 130 minutes (average 55 minutes).The intraoperative blood loss was 60-150 mL, and no one needed transfusion.The prostate gland excised weight was 18-72 g. There were no intestinal and bladder perforation, no transurethral resection syndrome (TURS) or obturator nerve reflex occurs, and no urinary incontinence or death.IPSS score was nine and the maximal average uroflow was 16.7 mL/s during the 2-6 month follow-up. Conclusion PKRP is one of the ideal methods treating benign prostatic hyperplasia, especially for high-risk patients with benign prostatic hyperplasia.
鐵氧體磁性納米材料（MFNPs）在生物醫(yī)學(xué)領(lǐng)域具有較大應(yīng)用潛力，如磁共振成像、靶向遞藥、磁熱治療、基因遞送等。MFNPs能夠在磁場(chǎng)作用下發(fā)生遷移運(yùn)動(dòng)，并靶向定位到目標(biāo)細(xì)胞或組織。但是要將MFNPs應(yīng)用到生物體內(nèi)，需進(jìn)一步在MFNPs表面進(jìn)行修飾。本文對(duì)MFNPs常見(jiàn)的修飾方法進(jìn)行了綜述，并總結(jié)了它在生物成像、醫(yī)學(xué)檢測(cè)以及生物治療等醫(yī)學(xué)領(lǐng)域中的應(yīng)用，進(jìn)一步展望了MFNPs的未來(lái)應(yīng)用方向。